Difficulty: Intermediate | Prerequisites: Cell cycle, mitosis, DNA replication
Big Picture
The cell cycle does not run on autopilot. A series of protein checkpoints inspects the cell at key moments, deciding whether it is safe to proceed with division. When the genes that encode these checkpoint proteins are mutated, cells can divide without restraint, forming tumours and potentially spreading through the body. This topic brings together everything from the DNA replication and cell division units and shows what goes wrong when the control systems fail. You should already be comfortable with the stages of the cell cycle and the basics of gene expression.
The cell cycle is regulated by internal checkpoints that use cyclins and cyclin-dependent kinases (CDKs) to decide whether a cell should keep dividing. When mutations hit the genes for these regulators (turning proto-oncogenes into oncogenes, or knocking out tumour suppressors), cells can divide without limit, forming tumours. If a tumour acquires the ability to invade other tissues (metastasis), it is malignant, which is what we call cancer.
Cyclins
A family of regulatory proteins whose concentrations rise and fall during the cell cycle. They activate cyclin-dependent kinases (CDKs) at specific points, driving the cell forward through the cycle.
Think of cyclins as timed signals that tell the cell "it is time to move to the next stage."
Cyclin-dependent kinases (CDKs)
Enzymes that phosphorylate target proteins to trigger cell-cycle events, but only when bound to their partner cyclin. Without the cyclin, the CDK is inactive.
CDKs are the engine; cyclins are the ignition key.
Checkpoints
Built-in surveillance points in the cell cycle (at G1, G2, and during M phase) where the cell pauses to verify that conditions are right before proceeding. They check for DNA damage, complete replication, and correct chromosome attachment.
Think of checkpoints as quality-control inspectors on a production line: if something is wrong, they halt the line until it is fixed.
Proto-oncogene
A normal gene that codes for a protein involved in cell growth, division, or survival. When functioning correctly, proto-oncogenes help regulate orderly cell division.
These are the normal, healthy versions of growth-promoting genes.
Oncogene
A mutated or overexpressed version of a proto-oncogene that promotes uncontrolled cell division. Oncogenes are "gain-of-function" mutations: the protein becomes permanently active or is produced in excess.
In simple terms, an oncogene is a growth signal stuck in the "on" position.
Tumour suppressor gene
A gene whose protein product normally slows cell division, repairs DNA damage, or triggers apoptosis (programmed cell death) when damage is too severe. Loss-of-function mutations in tumour suppressors remove the brakes on cell division.
The classic example is p53, sometimes called "the guardian of the genome."
Mutagen
An agent (chemical, radiation, or virus) that causes changes (mutations) in DNA. Some mutagens are also carcinogens (cancer-causing agents).
Examples include UV radiation, cigarette smoke, and certain industrial chemicals.
Cancer
A group of diseases characterised by uncontrolled cell division resulting from accumulated mutations in genes that regulate the cell cycle. Cancer cells ignore normal growth signals and checkpoints.
Benign tumour
An abnormal mass of cells that grows slowly, remains localised, and does not invade surrounding tissues. Benign tumours are generally not life-threatening, though they can cause problems depending on their location.
Malignant tumour
An abnormal mass of cells that grows rapidly, invades surrounding tissues, and can spread to distant sites. Malignant tumours are cancerous.
Primary tumour
The original site where a cancer first develops.
Secondary tumour
A tumour that forms when cancer cells from the primary tumour spread to another part of the body and establish a new growth there.
Metastasis
The process by which cancer cells break away from a primary tumour, travel through the blood or lymphatic system, and form secondary tumours in distant organs.
This is what makes cancer dangerous: once it metastasises, it is much harder to treat.
The cell cycle has three major checkpoints:
G1 checkpoint (restriction point): assesses cell size, nutrient availability, growth factor signals, and DNA integrity. If conditions are not met, the cell enters G0 (a quiescent state) rather than proceeding to S phase.
G2 checkpoint: verifies that DNA replication is complete and free of errors before the cell enters mitosis.
M checkpoint (spindle assembly checkpoint): checks that all chromosomes are properly attached to spindle fibres at the metaphase plate before anaphase begins.
If damage is detected, the checkpoints can pause the cycle for repair, or trigger apoptosis (programmed cell death) if the damage is too severe.
Cyclins are proteins whose levels fluctuate through the cell cycle. Each phase has its own set of cyclins.
CDKs are enzymes that are always present but inactive on their own. A CDK becomes active only when it binds to its partner cyclin.
The cyclin-CDK complex phosphorylates target proteins, triggering the events of that phase (e.g. chromosome condensation, nuclear envelope breakdown).
After the phase is complete, the cyclin is degraded, inactivating the CDK until the next cyclin accumulates.
Proto-oncogenes are normal genes that code for growth factors, growth factor receptors, signal transduction proteins, or transcription factors involved in cell division.
A mutation (point mutation, gene amplification, or chromosomal translocation) can convert a proto-oncogene into an oncogene.
An oncogene produces a protein that is permanently active or overproduced, pushing the cell to divide even when it should not.
Oncogene mutations are dominant: a mutation in just one copy of the gene is enough to promote uncontrolled growth.
Tumour suppressor genes code for proteins that slow division, promote DNA repair, or trigger apoptosis.
Both copies of a tumour suppressor gene typically need to be inactivated ("two-hit hypothesis") before the braking function is lost.
p53 is the most commonly mutated tumour suppressor in human cancers. It normally halts the cell cycle when DNA damage is detected, giving repair enzymes time to fix the problem. If repair fails, p53 triggers apoptosis.
A single mutation is rarely enough. Cancer usually results from the accumulation of multiple mutations over time, affecting both oncogenes and tumour suppressors.
This is why cancer risk increases with age: more time allows more mutations to accumulate.
Mutagens (UV light, tobacco smoke, certain chemicals, some viruses) increase mutation rates and therefore cancer risk.
Benign: encapsulated, slow-growing, does not invade neighbouring tissues or metastasise. Often removable by surgery.
Malignant: invasive, can metastasise. Malignant tumours are cancerous.
Primary: the site where the cancer originated.
Secondary (metastatic): a new tumour formed at a distant site by cells that broke away from the primary tumour and travelled through the bloodstream or lymphatic system.
Metastasis is the hallmark of advanced cancer. Cancer cells lose normal cell adhesion, enter the blood or lymph, and colonise distant organs.
Secondary tumours often appear in the lungs, liver, bones, or brain because these organs receive large volumes of blood.
Metastatic cancer is harder to treat because it is no longer localised.
Many cancer treatments target the cell cycle directly. Chemotherapy drugs like taxol stabilise spindle fibres so cells cannot complete mitosis. Targeted therapies block specific oncogene products (e.g. imatinib blocks the BCR-ABL fusion protein in chronic myeloid leukaemia). Immunotherapy helps the immune system recognise and destroy cells that have escaped checkpoint control.
Genetic testing for mutations in tumour suppressors like BRCA1 and BRCA2 allows people with a family history of cancer to assess their risk and make informed decisions about screening and preventive care.
Students often think a single mutation causes cancer. In most cases, cancer requires multiple mutations accumulating over time in the same cell lineage, affecting both growth-promoting and growth-restraining genes.
A common error is confusing oncogenes with tumour suppressor genes. Oncogenes are gain-of-function (accelerator stuck on). Tumour suppressor mutations are loss-of-function (brakes removed). Both contribute to cancer, but through opposite mechanisms.
Students sometimes believe all tumours are cancerous. Benign tumours are not cancer. Only malignant tumours, which invade surrounding tissue and can metastasise, are cancerous.
Another misconception is that mutagens and carcinogens are the same thing. All carcinogens are mutagens, but not all mutagens cause cancer (some mutations occur in genes unrelated to cell-cycle control).
⚠️ Know the three checkpoints (G1, G2, M) and what each one checks for. Expect a question asking you to explain how checkpoints prevent damaged cells from dividing.
⚠️ Understand the relationship between cyclins and CDKs. A common exam question asks what happens if cyclin levels fail to drop after a phase is complete (the cell keeps going when it should stop).
⚠️ Be able to explain the difference between a proto-oncogene and an oncogene, and why oncogene mutations are dominant.
⚠️ Know what p53 does and why its loss is significant. p53 is the most frequently tested tumour suppressor.
⚠️ Distinguish between benign, malignant, primary, and secondary tumours. These definitions are standard short-answer material.
⚠️ Define metastasis and explain why it makes cancer more dangerous and harder to treat.
True or false: CDKs are active on their own without cyclins. (False. CDKs require binding to a cyclin to become active.)
Fill in the blank: A mutated proto-oncogene that promotes uncontrolled cell division is called a(n) ______. (Oncogene.)
True or false: A benign tumour can metastasise to other organs. (False. Only malignant tumours metastasise.)
Fill in the blank: The tumour suppressor gene most commonly mutated in human cancers is ______. (p53.)
True or false: Cancer typically results from a single mutation in one gene. (False. Cancer usually requires multiple mutations accumulating over time.)
Q: How do protein checkpoints help to control the cell cycle?
A: Checkpoints at G1, G2, and M phase monitor conditions such as cell size, DNA integrity, replication completeness, and proper spindle attachment. If problems are detected, checkpoint proteins halt the cycle to allow repair. If the damage is irreparable, they can trigger apoptosis. This prevents damaged or incomplete cells from dividing.
Q: How does a mutation to a gene impact gene expression? What if the gene is one related to controlling the cell cycle (oncogene)?
A: A mutation can alter the protein a gene produces, making it non-functional, overactive, or produced in abnormal amounts. If the mutated gene is a proto-oncogene, the resulting oncogene may produce a protein that is permanently active, driving the cell to divide without normal growth signals. This is one step toward uncontrolled proliferation.
Q: Define the term cancer.
A: Cancer is a group of diseases in which cells divide uncontrollably due to accumulated mutations in genes that regulate the cell cycle, such as oncogenes and tumour suppressor genes. Cancer cells bypass normal checkpoints and can invade surrounding tissues and spread to other parts of the body.
Q: Describe the difference between benign and malignant tumours.
A: A benign tumour is a localised, slow-growing mass that does not invade surrounding tissues or spread to other sites. A malignant tumour is invasive, grows rapidly, and can metastasise to distant organs through the blood or lymphatic system. Only malignant tumours are classified as cancer.
Q: What is metastasis?
A: Metastasis is the spread of cancer cells from the primary tumour to distant sites in the body, where they form secondary tumours. This occurs when cancer cells enter the bloodstream or lymphatic system and colonise other organs.
Q: Distinguish between a primary and a secondary tumour.
A: A primary tumour is the original site where the cancer developed. A secondary tumour is a new growth at a different location, formed by cancer cells that spread from the primary tumour via metastasis.
Q: Explain the role of cyclins in cell cycle regulation.
A: Cyclins are regulatory proteins whose concentrations rise and fall at specific stages of the cell cycle. They bind to and activate cyclin-dependent kinases (CDKs), which then phosphorylate target proteins to drive the cell through that phase. When the cyclin is degraded, the CDK becomes inactive, and the cell cannot proceed until the next cyclin accumulates.
This topic depends directly on the cell cycle and mitosis material in the companion cell-division notes. Checkpoints exist to catch errors introduced during DNA replication (covered in the DNA replication notes), and the mutations discussed here are the same kind of DNA-sequence changes covered in the genetics and molecular biology units.
Cancer biology also connects to the immune system unit later in the course: the immune system normally detects and destroys abnormal cells, and immunotherapy works by boosting that response.
Cancer, cell cycle control, checkpoints, G1 checkpoint, G2 checkpoint, M checkpoint, spindle assembly checkpoint, cyclins, cyclin-dependent kinases, CDKs, proto-oncogene, oncogene, tumour suppressor gene, p53, guardian of the genome, mutagen, carcinogen, benign tumour, malignant tumour, primary tumour, secondary tumour, metastasis, apoptosis, programmed cell death, uncontrolled cell division, two-hit hypothesis, gain-of-function mutation, loss-of-function mutation, Taq polymerase, BIO 101, cell division and cancer